Based on the metrics, I would recommend a HOLD on SUNPHARMA. The 12M return is positive, indicating a good long-term performance, while the short-term returns are flat, suggesting that the stock may be due for a rebound, and the Sharpe Ratio is strong, indicating a good balance of risk and return.